Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Assessing Biodistribution of LNP-mRNA Therapeutics Across Multiple Tissue Matrices in NHP Models

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES.

Assessing Biodistribution of LNP-mRNA Therapeutics Across Multiple Tissue Matrices in NHP Models

Biodistribution of LNP-mRNA Therapeutics in nonhuman primate Models

CELL & GENE | RNA | BIOLOGICS

A close-up of a Pall Corporation single-use bioreactor system in a cleanroom environment, showing the control panel, vessel with cell culture media, and tubing.

A well-defined biodistribution profile is fundamental to the preclinical development of Advanced Therapeutics and Complex Biologics. For programs centered on lipid nanoparticle (LNP) delivery of RNA payloads, understanding tissue tropism and off-target accumulation is a primary determinant of the safety package. Applying proven intelligence in bioanalytical method development supporting LNP delivered therapies, propels these next-generation therapeutics toward IND submissions.

Frequently Asked Questions

    Why are nonhuman primate (NHP) models preferred for LNP-mRNA biodistribution studies?

    Nonhuman primate (NHP) models are selected for their high degree of physiological and immunological similarity to humans. Their lipid metabolism, protein binding characteristics, and immune system responses provide a more predictive data set for human clinical outcomes compared to rodent models, particularly for assessing potential off-target effects of novel LNP formulations.

    What are the primary analytical methods for quantifying mRNA distribution in tissue?

    Quantitative reverse transcription PCR (RT-qPCR) is the standard for sensitive and specific quantification of mRNA payloads across a wide range of tissue and fluid matrices. These assays are developed and qualified in a phase-appropriate manner under GxP guidelines to ensure data integrity for regulatory submissions.

    How does LNP composition influence biodistribution?

    The specific formulation of ionizable lipids, helper lipids, cholesterol, and PEG-lipids directly governs tissue targeting, cellular uptake, and clearance kinetics. Modifying these components can shift distribution from the liver to other tissues, making precise, multi-tissue analysis necessary for each unique therapeutic candidate.

A Tailored Preclinical Strategy for LNP Delivery

A standardized testing template does not exist for assessing the biodistribution of LNP-delivered RNA. Each therapeutic program requires a data-driven preclinical strategy tailored to its specific payload (e.g., mRNA, siRNA, gRNA) and the novelty of its delivery system. The objective is to build a comprehensive map of where the LNP and its payload distribute post-administration and to quantify their persistence over time.

Recent advancements in lipid chemistry focus on creating biodegradable ionizable lipids and novel amidine-incorporated lipids to refine delivery and improve safety profiles (PMID: 40060499, PMID: 38982196). As these delivery systems become more sophisticated, the bioanalytical methods used to track them must offer equivalent precision.

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

Multi-Matrix Quantification for Regulatory Confidence

Our approach centers on robust RT-qPCR analysis across a comprehensive panel of tissues and biofluids. This generates the high-resolution data required for IND-enabling toxicology studies and provides a clear picture of on-target delivery and off-target liabilities.

  • Broad Tissue Panels: Analysis extends beyond primary target organs to include spleen, lymph nodes, bone marrow, heart, brain, and gonads to build a complete safety profile.
  • Phase-Appropriate Assays: All methods are developed and qualified to meet GxP standards, ensuring regulatory acceptance and data integrity.
  • High-Resolution Data: Sensitive quantification provides definitive answers on payload concentration and persistence in each matrix, supporting risk assessment.

This detailed characterization is built upon the scientific discipline and operational expertise that enabled our core team to achieve a 100% successful IND rate for client programs since 2019. That proven intelligence now powers Franklin Biolabs, launched in 2024 to accelerate the next generation of Advanced Therapeutics.

Learn more about our core Bioanalytical Services.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities